Platinum analogues

Cancer Chemotherapy and Biotherapy: Principles and Practice

Volumn , Issue , 2011, Pages 769-798

  Reed, Eddie ^a   Chabner, Bruce A ^b  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85052765624     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (106)

1. Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965;205:698.
2. Rosenberg B, Van Camp L, Trosko JE., et al. Platinum compounds: a new class of potent antitumor agents. Nature 1969;222:385-386.
3. Reed E, Dabholkar M, Chabner BA. Platinum analogues. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy, 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1996:357-378.
4. Reed E. Cisplatin and analogs. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy: Principles and Practice, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2001:447-465.
5. Burger KN, Staffhorst RW, Vijlder HC., et al. Nanocapsules: lipid coated aggregates of cisplatin with high toxicity. Nat Med 2002; 8:81-84.
6. Chupin V, de Kroon AI, de Kruijff B. Molecular architecture of nanocapsules, bilayer enclosed solid particles of cisplatin. J Am Chem Soc 2004;126:13816-13821.
7. Hamelers IH, de Kroon AI. Nanocapsules: a novel formulation technology for platinum-based anticancer drugs. Future Lipidol 2007;2:445-453.
8. Hamelers IH, van Loenen E, Staffhorst RW., et al. Carboplatin nanocapsules: a highly cytotoxic, phospholipid-based formulation of carboplatin. Mol Cancer Ther 2006;5:2007-2012.
9. Kruh GD. Lustrous insights into cisplatin accumulation: copper transporters. Clin Cancer Res 2003;9:5807-5809.
10. Samini G, Katano K, Holzer AK., et al. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol 2004;66:25-32.
11. Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 2006; 70:1390-1394.
12. Zhang S, Levejoy KS, Shima JE., et al. Organic cation transporters are determinants of oxaliplatin cytoxicity. Cancer Res 2006; 66:8847-8857.
13. Ciarimboli G, Ludwig T, Lang D., et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005;167:1477-1484.
14. Eastman A. Reevaluation of interaction of cis-dichloro (ethylene-diammine) platinum(II) with DNA. Biochemistry 1986; 25:3912-3915.
15. Eastman A, Schulte N, Sheibani N., et al. Mechanisms of resistance to platinum drugs. In: Nicolini M, ed. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Boston: Martinus Nijhoff, 1988:178-196.
16. Fichtinger-Schepman AM, van der Veer JL, den Hartog JH., et al. Adducts of the antitumor drug cisdiamminedichloroplatinum (II), with DNA: formation, identification and quantitation. Biochemistry 1985; 24:707-713.
17. Fichtinger-Schepman AMJ, van Oosterom AT, Lohman PHM., et al. Cis-diamminedichloroplatinum(II)-induced adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res 1987;47:3000-3004.
18. Fichtinger-Schepman AMJ, van Oosterom AT, Lohman PHM., et al. Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay? Mutat Res 1987;190:59-62.
19. Fichtinger-Schepman AM, van Dijk-Knijnenburg HC, van der Velde-Visser SD., et al. Cisplatin and carboplatin DNA adducts: is PT-AG the cytotoxic lesion? Carcinogenesis 1995;16:2447-2453.
20. Gelasco A, Lippard SJ. NMR solution structure of a DNA dodecamer duplex containing a cisdiammineplatinum( II) d(GpG) intrastrand cross-link, the major adduct of the anti-cancer drug cisplatin. Biochemistry 1998;37:9230-9239.
21. Sancar A. Mechanisms of DNA excision repair. Science 1994; 266:1954-1956.
22. De Laat WL, Jaspers NG, Hoeijmakers JH. Molecular mechanism of nucleotide excision repair. Genes Dev 1999;13:768-785.
23. Reed E. Platinum-DNA adduct, nucleotide excision repair, and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24:331-344.
24. Micetich K, Barnes D, Etickson LC. A comparative study of the cytotoxicity and DNA-damaging effects of cis-diammino(1,1 cyclobutanedicarboxylato)-platinum(II) and cisdiamminedichloroplatinum (II) on LI210 cells. Cancer Res 1985;45:4043-4047.
25. Reardon JT, Vaisman A, Chaney SG., et al. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-amminedichloro-cyclohexylamineplatinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999;59:3968-3971.
26. Luo FR, Wyrick SD, Chaney SG. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol Res 1998;10:595-603.
27. Saris CP, van de Vaart PJ, Rietbrock RC., et al. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 1996;17:2763-2769.
28. Raymond E, Faivre S, Chaney SG., et al. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002;1:227-235.
29. Olivero OA, Semino C, Kassim A., et al. Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells. Mutat Res 1995;346:221-230.
30. Olivero OA, Chang PK, Lopez-Larraza DM., et al. Preferential formation and decreased removal of cisplatin-DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA. Mutat Res 1997;391:79-86.
31. Giurgiovich AJ, Diwan BA, Olivero OA., et al. Elevated mitochondrial cisplatin-DNA adduct levels in rat tissues after transplacental cisplatin exposure. Carcinogenesis 1997;18:93-96.
32. Deyoung MP, Ellisen LW. p63 and p73 in human cancer: defining the network. Oncogene 2007;26:5169-5183.
33. Aebi S, Fink D, Gordon R., et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 1997;3:1763-1767.
34. Drummond JT, Anthoney A, Brown R., et al. Cisplatin and adriamycin resistance are associated with MutL-alpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996;271:19645-19648.
35. Nehma A, Baskaran R, Nebel S., et al. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair proficient and -deficient cells. Br J Cancer 1999;79:1104-1110.
36. Vaisman A, Varchenko M, Umar A., et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998;58: 3579-3585.
37. Siemer S, Ornskov D, Guerra B., et al. Determination of mRNA and protein levels of p53, MDM2, and protein kinase CK2 subunits in F9 cells after treatment with the apoptosis-inducing drugs cisplatin and carboplatin. Int J Biochem Cell Biol 1999;31:661-670.
38. Arriola EL, Rodriguez-Lopez AM, Hickman JA., et al. Bcl-2 over expression results in reciprocal downregulation of Bcl-X(L) and sensitizes human testicular germ cell tumors to chemotherapy-induced apoptosis. Oncogene 1999;18(7):1457-1464.
39. Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 1999;59:3077-3083.
40. Sharma S, Gong P, Temple B., et al. Molecular dynamic simulations of cisplatin-and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics. J Mol Biol 2007;373:1123-1140.
41. Rothenberg ML, Oza AM, Bigelow RH., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059-2069.
42. Villella J, Marchetti D, Odunsi K., et al. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma. Gynecol Oncol 2004;95:539-545.
43. Engblom P, Rantanen V, Kulmala J., et al. Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. Br J Cancer 1999;79:286-292.
44. Donawho CK, Luo Y, Luo Y., et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-2737.
45. Altaha R, Liang X, Yu JJ. Reed Excision repair cross complementing-group-1: gene expression and platinum resistance. Int J Mol Med 2004;14:959-970.
46. Li Q, Bostick-Bruton F, Reed. E. Modulation of ERCC-1 mRNA expression by pharmacological agents in human ovarian cancer cells. Biochem Pharmacol 1999;57:347-353.
47. Li Q, Bostick-Bruton F, Reed E. Effect of interleukin-1 and tumor necrosis factor on cisplatin-induced ERCC1 mRNA expression in a human ovarian carcinoma cell line. Anticancer Res 1998;18:2283-2287.
48. Mimnaugh EG, Yunmbam MK, Li Q., et al. Proteasome inhibitors prevent cisplatin-DNA adduct repair and potentiate cisplatin-induced apoptosis in ovarian carcinoma cells. Biochem Pharmacol 2000;60:1343-1354.
49. Bonovich M, Olive M, Reed E., et al. Adenoviral delivery of A FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines. Cancer Gene Ther 2002;9:62-70.
50. Von Knethen A, Lotero A, Brune B. Etoposide and cisplatin induced apoptosis in activated RAW 264.7 macrophages is attenuated by cAMP-induced gene expression. Oncogene 1998;17:387-394.
51. Kleinerman ES, Zwelling L A, Howser D., et al. Defective monocyte killing in patients with malignancies and restoration of function during chemotherapy. Lancet 1980;2(8204):1102-1105.
52. Kleinerman ES, Zwelling LA, Muchmore AV. Enhancement of naturally occurring human spontaneous monocyte mediated cytotoxicity by cis-diamminedichloroplatinum(II). Cancer Res 1980;40:3099-3102.
53. Merritt RE, Mahtabifard A, Yamada RE., et al. Cisplatin augments cytotoxic T lymphocyte mediated antitumor immunity in poorly immunogenic murine lung cancer. J Thorac Cardiovasc Surg 2003;126:1609-1617.
54. Li Q, Gardner K, Zhang L., et al. Cisplatin induction of ERCC1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 1998;273:23419-23425.
55. Li Q, Tsang B, Gardner K., et al. Phorbol ester exposure activates an AP-1 associated increase in ERCC1 mRNA expression in human ovarian cancer cells. Cell Mol Life Sci 1999;55:456-466.
56. Gupta S, Natarajan R, Payne SG., et al. Deoxycholic acid activates the c-Jun N-terminal kinase pathway via Fas receptor activation in primary hepatocytes. Role of acidic sphingomyelinase-mediated ceramide generation in Fas receptor activation. J Biol Chem 2004;279:5821-5828.
57. Schwabe RF, Uchinami H, Qian T, et al Differential requirement for c-Jun NH2-terminal kinase in TNF alpha-Fas-mediated apoptosis in hepatocytes. FASEB J 2004;18:720-722.
58. Shangary S, Lerner EC, Zhan Q., et al. Lyn regulates the cell death response to ultraviolet radiation through c-Jun N terminal kinase-dependent Fas ligand activation. Exp Cell Res 2003;289:67-76.
59. Toh U, Sudo T, Kido K., et al. Intraarterial cellular immunotherapy for patients with inoperable liver metastases of esophageal cancer. Gan To Kagaku Ryoho 2002;29:2152-2156.
60. Berghmans T, Paesmans M, Lalami Y., et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma; a systematic review of the literature with meta-analysis. Lung Cancer 2002;38:111-121.
61. Yoshikawa T, Tsuburaya A, Kobayashi O., et al. A combination immunochemotherapy of 5-fluorouracil, cisplatin, leucovorin, and OK-432 for advanced and recurrent gastric carcinoma. Hepatogastroenterology 2003;50:2259-2263.
62. Lens MB, Eisen TG. Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother 2003;4:2205-2211.
63. Ohtsukasa S, Okabe S, Yamashita H., et al. Increased expression of ECA and MHC class I in colorectal cancer cells exposed to chemotherapy drugs. J Cancer Res Clin Oncol 2003;129:719-726.
64. Wilailak S, Dangprasert S, Srisupundit S. Phase I clinical trial of chemoimmunotherapy in combination with radiotherapy in stage IIIB cervical cancer patients. Int J Gynecol Cancer 2003;13:652-656.
65. Godwin A, Meister A, O'Dwyer P., et al. High resistance to cisplatin in human ovarian cacer cell lines is associated with marked increase in glutathione systhesis. Proc Natl Acad Sci U S A 1992;89:3070-3074.
66. Hosking LK, Whelan RDH, Shellard SA., et al. An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumor agents shown by a range of human tumour cell lines. Biochem Pharmacol 1990;40:1833-1842.
67. Pattaniak A, Bachowski G, Laib J., et al. Properties of the reaction of cis-dichlorodiammineplatinum(II) with metallothionein. J Biol Chem 1992;267:16121.
68. Kelley S, Basu A, Teicher B., et al. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988;241:1813-1815.
69. Reed E, Ozols RF, Tarone R., et al. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A 1987;84:5024-5028.
70. Reed E, Ostchega Y, Steinberg S., et al. An evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res 1990;50:2256-2260.
71. Darcy KM, Tian C, Reed E.A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair complementation group 1expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Cancer Res 2007;67:4474-4481.
72. Dabholkar M, Bostick-Bruton F, Weber C., et al. ERCCI and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992;84:1512-1517.
73. Dabholkar M, Vionnet JA, Bostick-Bruton F., et al. mRNA Levels of XPAC and ERCC1 in ovarian tumor tissue correlates with response to platinum containing chemotherapy. J Clin Invest 1994;94:703-708.
74. Metzger R, Leichman CG, Danenberg KD., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-316.
75. Shirota Y, Stoehlmacher J, Brabender J., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298-4304.
76. Lord RV, Brabender J, Gandara D., et al. Low ERCC1 expression correlates with prolonges survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-2291.
77. Rosell R, Taron M, Barnadas A., et al. Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer. Cancer Control 2003;10:297-305.
78. Li Q, Yu JJ, Mu C., et al. Association between the level of ERCC1 expression and the repair of cisplatininduced DNA damage in human ovarian cancer cells. Anticancer Res 2000;20(2A):645-652.
79. Wang G, Reed E, Li QQ. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer. Oncol Rep 2004;12: 955-965.
80. Ferry K, Hamilton T, Johnson S. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role for ERCC1-XPF. Biochem Pharmacol 2000;60:1305-1313.
81. Lee KB, Parker RJ, Bohr VA., et al. Cisplatin sensitivity/resistance in UV-repair deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 1993;14:2177-2180.
82. Taniguchi T, Tischkowitz M, Ameziane N., et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9:568-574.
83. Rottenberg S, Jaspers JE, Kersbergen A, et. al. High sensitivity of BRCA 1-deficient mammary tumors to the PARP inhibitor ASD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008;105:170794-170784.
84. Furuta T, Ueda T, Aune G., et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002;62:4899-4902.
85. Zhen W, Link CJ Jr, O'Connor PM., et al. Increased genespecific repair of cisplatin interstrand crosslinks in cisplatin resistant human ovarian cancer cells. Mol Cell Biol 1992;12:3689-3698.
86. Jones JC, Zhen W, Reed E., et al. Preferential DNA repair of cisplatinum lesions in active genes in CHO cells. J Biol Chem 1991;266:7101-7107.
87. Olaussen KA, Dunant A, Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991.
88. Viguier J, Boige V, Miquel C., et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin-5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005;11:6212-6217.
89. Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin: a review. Gynecol Oncol 1993;50:147-158.
90. Reed E, Jacob J. Carboplatin and renal dysfunction. Ann Intern Med 1989;110:409.
91. Reed E, Jacob J, Brawley O. Measures of renal function in cisplatin-related chronic renal disease. J Natl Med Assoc 1991;83:522-526.
92. Diaz-Rubio E, Sastre J, Zaniboni A. Oxaliplatin as a single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998;9:105-108.
93. Takimoto CH, Graham MA, Lockwood G., et al. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res 2007;13:4832-4839.
94. Extra JM, Espie M, Calvo F., et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990;25(Suppl 5):299-303.
95. Hesketh PJ. Chemotherapy induced nausea and vomiting. N Engl J Med 2008;358:2482-2494.
96. Wiernik PH, Yeap B, Vogl SE., et al. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest 1992;10:1-9.
97. Travis LB, Holowaty EJ, Bergfeldt K., et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999;340:351-357.
98. Burkard R, Trautwein P, Salvi R. The effects of click level, click rate, and level of background masking noise on the inferior caliculus potential (ICP) in the normal and carboplatin treated chinchilla. J Acoust Soc Am 1997;102(6):3620-3627.
99. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-609.
100. Markman M, Rothman R, Hakes T., et al. Second line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-393.
101. Reed E, Jacob J, Ozols RF., et al. 5-Fluouracil and leucovorin in platinum-refractory advanced stage ovarian cancer. Gynecol Oncol 1992;46:326-329.
102. Silver DP, Richardson AJ, Eklund AC., et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28(Jan 25, 2010 online).
103. Byrski T, Gronwald J, Huzarski T, et. al. Pathologic complete response rates in young women with BRCA1-positive breast cancer after neoadjuvant chemotherapy. J Clin Oncol 2010;28:375-379.
104. Sternberg CN, Petrylak DP, Sartor O., et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer pregressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009;27:5431-5438.
105. Kelland LR, Abel G, McKeage MJ., et al. Preclinical antitumor evaluation of bis-acetato-amminedichloro-cyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res 1993;53:2581-2586.
106. Yang J, Parsons J, Nicolay NH., et al. Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy. Oncogene 2010;29:463-468.